Global Innovative Platforms is a pre-revenue startup developing a non-invasive breath test to detect heartworm in dogs. The company's core product under development — the Heartworm Breath Test — uses gas chromatography to analyze volatile organic compounds (VOCs) in a dog's breath, then applies AI software to identify breath patterns associated with heartworm infection. The key claimed advantage over existing blood-based tests is earlier detection, before the 6-month maturity threshold required for current antigen tests, and without drawing blood. The intended customers are veterinarians and animal healthcare facilities, with the company envisioning a per-use fee model for units placed at veterinary clinics. The company has no revenue, one full-time employee, and is entirely in R&D. The Heartworm Breath Test consists of three components: a muzzle-fitted breath collection device, a licensed gas chromatograph (the VOCAM Plus), and Ellvin, proprietary AI software developed by Defiant Technologies that analyzes VOC patterns. Global Innovative Platforms licenses its core technology from Defiant Technologies, owing $250,000 in installment payments plus a 3% royalty on net sales. The company does not own any patents. Beyond heartworm, the company intends to expand to a multi-disease panel of up to nine canine diseases detectable from a single breath sample, though this has no defined timeline. The company expects to complete verification, validation, and commercialization readiness by 2026, and requires additional external financing to execute its business plan.